<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Currently, no evidence suggests that immunoglobulin therapy (intravenous or subcutaneous), plasma exchange, or Fc receptor antagonists (efgatirgimod, currently tested in clinical trials for myasthenia gravis (MG)) [
 <xref ref-type="bibr" rid="CR40">40</xref>] may increase the risk of infection or a severe disease course.
</p>
